News Releases
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs
January 14, 2025 – Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc., Provectus’s Founded Entity that is developing novel ocular therapeutics.
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics
January 14, 2025 — VisiRose Inc. today announced the closing of a $3 million seed financing round.
